Clin2
NCT07769333Possibly a fitNot yet recruiting

Rituximab and steroids for pemphigus

Pemphigus VulgarisRituximab (RTx)

Treatments studied

Part of Immune system & allergy, Skin clinical trials.

This trial compares two treatment combinations for moderate-to-severe pemphigus: rituximab plus steroids versus steroids plus azathioprine. The goal is to find which approach controls the disease better while reducing side effects.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
92 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must be between 18 and 65 years old.
  • You must have moderate to severe pemphigus vulgaris that is either newly diagnosed or flaring up.
  • Your diagnosis must be confirmed by a skin biopsy and a special test called direct immunofluorescence.
  • You cannot be pregnant or nursing, and you must not have a serious infection or active cancer.
  • You must not have had rituximab treatment within the last 12 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07681388Recruiting
CAR-T cell therapy for hard-to-treat pemphigus

This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.

Wuhan, Hubei
NCT04422912Recruiting· Phase 1/Phase 2
Cell therapy trial for active pemphigus vulgaris

This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.

Redwood City, California
NCT06581562Recruiting· Phase 1
Testing rituximab plus AB-101 for autoimmune diseases

This trial tests a new treatment (AB-101) combined with rituximab for people with certain autoimmune diseases like rheumatoid arthritis, pemphigus vulgaris, vasculitis, or lupus. It is for those who have not had success with standard therapies.

Plantation, Florida
NCT05898308Recruiting· Phase 4
Test a personalized maintenance plan for pemphigus

This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.

Amiens
NCT07641725Recruiting
Light Therapy and Steroid Rinse for Pemphigus Mouth Sores

This study tests whether a steroid mouthwash and/or light therapy (photobiomodulation) can help heal painful mouth sores caused by pemphigus vulgaris, an autoimmune disease that damages the inside of the mouth and skin.

Damascus
NCT05514015Recruiting· Phase 4
Rituximab with steroids or rituximab alone for membranous kidney disease

This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.

Guangzhou, Guangdong

Hear when a new Pemphigus Vulgaris trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.